Oslo, Norway (19 February 2020) - Based on the power of attorney granted at the
annual general meeting of NattoPharma ASA ("NattoPharma" or "Company") on May
29th, 2019, and the option program related to defined operational objectives
approved by the Board of Directors in 2019, the Board of Directors of
NattoPharma has in board proceedings February 18th, 2020 granted a total of 155
000 options to executive management, other employees and strategic partners.
Options are granted based on performance against defined criteria and metrics.

The following persons on the executive management team have been granted
options;

Name         Shares  Granted  Options Prior to Grant  Options after Grant
              Owned  Options
Kjetil          300   50 000                 225 100              275 100
Ramsøy, CEO     000
& CFO

Other employees and partners have been granted a total of 105 000 options.

The options have an exercise price equal the closing price on Oslo Axess on
February 18[th], 2020, which is equal to NOK 9,20. The options granted are
vested immediately and may be exercised up to and including March 31[st], 2023.

Further, in conjunction with the hiring of the new Chief Financial Officer in
NattoPharma the Board of Directors has in board proceedings February 18th, 2020
granted a total of 30,000 options to Robert Schrama who will start in the new
position on March 9th, 2020. Mr. Schrama holds no shares or options in
NattoPharma ASA prior to this grant. His total holding of shares and options
following this grant is 30,000 options.

The options will have an exercise price equal the closing price on Oslo Axess on
March 9th, 2020. The options granted are fully vested on September 9th, 2020 and
may be exercised up to and including March 31st, 2023.

X X X

For more information, please contact:

Kjetil Ramsøy,

CEO, NattoPharma

E-mail: kjetil.ramsoy@nattopharma.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.